What is Nomic?
Nomic Bio offers a protein profiling service that distinguishes itself with exceptional speed and seamless integration, delivering results in as little as one week. Its proprietary nELISA platform leverages advanced DNA nanotechnology to facilitate high-throughput proteomics, capable of processing over 10,000 samples weekly. The company emphasizes cost-efficiency and flexible multiplexing, targeting researchers and companies within the biotechnology and pharmaceutical sectors. Nomic Bio's technology is designed to enhance drug discovery pipelines and accelerate the pace of scientific research by providing comprehensive proteomic analyses.
How much funding has Nomic raised?
Nomic has raised a total of $59M across 2 funding rounds:
Series A
$17M
Series B
$42M
Series A (2021): $17M with participation from SR One, Lux Capital, and Casdin Capital
Series B (2024): $42M led by Lux Capital, Real Ventures, Amplitude Ventures, and Avant Bio
Key Investors in Nomic
Lux Capital
Lux Capital is a New York-based venture capital firm that invests in early-stage and growth-stage companies at the intersection of science and technology, including AI, robotics, space, defense, biotechnology, and advanced materials.
Real Ventures
Real Ventures backs visionary founders building innovative tech companies with large-scale positive impacts on society, providing guidance and stage-specific help for global success.
Amplitude Ventures
Amplitude Venture Capital deploys a growth model to scale Canadian precision medicine companies, with offices in Montreal, Toronto, and Vancouver.
What's next for Nomic?
With the recent influx of capital, Nomic Bio is poised to scale its operations and enhance its market presence. The strategic investment suggests a focus on expanding its technological capabilities and potentially forging key partnerships within the life sciences ecosystem. Future developments will likely involve further validation of its nELISA platform across diverse research applications and a push towards broader commercial adoption. The company's growth trajectory indicates a strong potential for market leadership in advanced proteomics solutions, supporting the development of novel therapeutics and accelerating scientific breakthroughs.
See full Nomic company page
